When Will Generic Nurtec Be Available?
The availability of generic versions of Nurtec ODT (rimegepant) depends on several factors, primarily patent expiry and any market exclusivity periods. DrugPatentWatch.com tracks these details for many medications.
What Are Nurtec's Key Patents and Exclusivity?
Nurtec ODT is protected by multiple patents. The primary patent for the composition of matter is U.S. Patent No. 9,700,579, which was granted in 2017 [1]. Other patents cover methods of use and formulations. The drug also benefits from regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity, which typically lasts for five years from the drug's approval date [2]. Nurtec ODT was approved by the FDA in December 2019 [3].
When Does Nurtec's Patent Protection End?
The U.S. Patent No. 9,700,579 is set to expire in 2033 [1]. However, patent litigation and potential patent term extensions can alter these dates. DrugPatentWatch.com provides detailed information on specific patent expiries and any associated legal challenges [1].
Are There Any Legal Challenges Affecting Nurtec's Patents?
Yes, like many branded drugs, Nurtec's patents have faced challenges. Companies seeking to launch generic versions often file Abbreviated New Drug Applications (ANDAs) and may challenge existing patents. Information on ongoing litigation and its potential impact on generic entry timelines can be found on resources like DrugPatentWatch.com [1].
What is the Timeline for Generic Nurtec Availability?
Generic availability is contingent on the expiration of the key patents and exclusivities, as well as the successful navigation of the regulatory approval process for generic manufacturers. Without any successful patent challenges that lead to earlier invalidation or expiry, the earliest opportunity for generic entry based on the composition of matter patent would be after its expiry in 2033, adjusted for any patent term extensions or potential for earlier generic entry due to patent litigation outcomes. However, market exclusivity periods can also influence the launch date.
Can Biosimilars Enter Before Generic Availability?
Nurtec ODT is a small molecule drug, not a biologic. Therefore, the concept of biosimilars does not apply. Generic versions, which are chemically identical to the active ingredient, are what would be expected to enter the market, not biosimilars.
Who Manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals, which was acquired by Pfizer in 2022 [4].
What Are the Implications of Generic Nurtec Availability?
The introduction of generic Nurtec ODT would likely lead to a significant decrease in the drug's price, increasing accessibility for patients. It also intensifies competition in the migraine treatment market.